The usual reason for such sudden fatalities is given as massive cardiac arrests or fatal brain strokes. However, everybody ...

This study is an open-label, dose-escalation/expansion Phase I clinical trial (NCT05920876), aiming to assess the safety of ...

Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly half. "Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which ...

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...